Glass House Brands (GLAS) Convertible Debt (2020)
Glass House Brands (GLAS) posted quarterly Convertible Debt of $7.4 million for Q4 2020.
Glass House Brands (GLAS) Convertible Debt (2020) Analysis & Trends
Glass House Brands (GLAS) has reported Convertible Debt for 1 consecutive years, with $7.4 million the latest figure, recorded in Q4 2020.
- In Q4 2020, Convertible Debt changed N/A year-over-year to $7.4 million; the TTM figure through Dec 2020 stood at $7.4 million (changed N/A YoY), while the FY2020 annual figure was $7.4 million, changed N/A from the prior year.
- Convertible Debt held at $7.4 million in Q4 2020 per GLAS's latest filing.
- Across five years, Convertible Debt topped out at $7.4 million in Q4 2020 and bottomed at $7.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Glass House Brands | 825.81 Mn | 807.26 Mn | 15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 7.37 Mn |